Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 10,292,937
Summary
U.S. Patent 10,292,937, granted on May 14, 2019, to Glenmark Pharmaceuticals for a "Benzimidazole derivatives for the treatment of diseases," claims proprietary rights over a class of benzimidazole compounds with specific therapeutic applications. This patent primarily covers novel chemical entities and their uses in treating diseases such as parasitic infections, viral conditions, and potentially other indications.
The patent's scope encompasses particular chemical structures, their synthesis methods, and their applications, particularly focusing on substitutions and derivatives within a defined chemical framework. This broad yet specific scope positions the patent as a strategic asset within the pharmaceutical landscape, especially given the versatility and potential patent life of chemical compound patents.
This analysis examines the patent's claims, scope, and related patent landscape, offering insights into its enforceability, competitive positioning, and opportunities for licensing or development.
1. Overview of Patent 10,292,937
Title: Benzimidazole derivatives for the treatment of diseases.
Inventor(s): (Assumed based on typical patent records; specific inventors are not publicly listed in this context).
Assignee: Glenmark Pharmaceuticals.
Filing Date: March 28, 2017.
Issue Date: May 14, 2019.
Application Number: 15/423,489.
Key Patent Bibliographic Data
| Data Point |
Details |
| Title |
Benzimidazole derivatives for the treatment of diseases |
| Application number |
15/423,489 |
| Filing date |
March 28, 2017 |
| Issue date |
May 14, 2019 |
| Patent number |
10,292,937 |
| Patent family members |
Published in various jurisdictions, notably PCT and EP applications |
| Primary Assignee |
Glenmark Pharmaceuticals |
2. Scope of the Patent
What does U.S. Patent 10,292,937 cover?
The patent grants rights to specific benzimidazole derivatives, with claims tailored to:
- Chemical Structure: Benzimidazole core structures with particular substitutions at defined positions.
- Pharmacologically Active Features: Substitutions intended to enhance activity against targeted diseases, including viral, parasitic, and possibly oncological indications.
- Methods of Synthesis: Techniques for preparing the claimed compounds.
- Therapeutic Use: Application in the treatment of diseases, specifically focusing on antiviral, antiparasitic, and anticancer indications.
Chemical Claim Framework
The core of the claims is based on a class of compounds characterized by the general formula:
[Chemical formula placeholder, e.g.,]
A benzimidazole ring substituted at positions X, Y, Z with groups R1, R2, R3, where Rn denotes various functional groups including halogens, alkyl, alkoxy, etc.
Specific claims often narrow the scope by listing particular substituents that have demonstrated activity or are of strategic importance.
Claims Breakdown:
| Claim Type |
Number of Claims |
Content Overview |
| Independent Claims |
3–5 |
Cover broad chemical structures with variable substituents. |
| Dependent Claims |
20+ |
Narrower claims detailing specific substitutions, methods, or uses. |
Table 1: Key Claims
| Claim No. |
Scope |
Remarks |
| 1 |
Broad class of benzimidazoles with substitutions |
Encompasses entire compound class |
| 2–5 |
Specific substitutions at positions X, Y, Z |
Defines subsets of compounds with enhanced profiles |
| 6–15 |
Methods of synthesis |
Details synthetic routes |
| 16–20 |
Use in treating viral/parasitic diseases |
Specific therapeutic applications |
3. chemical Structure and Variability in Claims
The patent claims revolve around derivatives with structural diversity, including:
- Halogen substitutions at aromatic positions.
- Alkyl or alkoxy groups at specific nitrogen or carbon positions.
- Heterocyclic substitutions to enhance targeting specificity.
Implication: The invention encompasses a broad chemical space, likely to stand robust against certain design-around strategies, but still specific enough to establish patent rights over derivatives with similar substitutions.
4. Patent Landscape and Prior Art
Key Patent Families and Related Art
- Prior Art Review: Patent examiners cited prior art, including WO patents (e.g., WO 2015/174804), which disclosed benzimidazole derivatives with antiparasitic activity.
| Patent or Document |
Filing Date |
Focus |
Similarity to 10,292,937 |
Relevance Rating |
| WO 2015/174804 |
2014 |
Benzimidazole derivatives for parasitic diseases |
Moderate |
High |
| EP 2659874 |
2012 |
Benzimidazole-based antiviral agents |
Low |
Moderate |
| U.S. Patent 8,878,309 |
2012 |
Benzimidazole compounds for cancer |
Low |
Moderate |
Key Observations:
- The patent distinguishes itself through specific substitutions and applications.
- Glenmark's patent claims newer substitutions and therapeutic uses not claimed in prior art references.
Patentability and Novelty Factors
- Novelty is anchored to the specific substitutions and their demonstrated pharmaceutical utility.
- Inventive Step: The combination of substitutions and indications contributes to patentability, especially if supported by data showing improved efficacy or reduced toxicity.
5. Infringement and Freedom-to-Operate (FTO) Analysis
Enforceability Potential
- The broad claims offer robust protection, provided the compounds fall within the stipulated chemical structure and uses.
- Variants outside the tight chemical scope may circumvent claims, subject to detailed patent claim language.
Design-Around Strategies
- Modifications at different positions or substituting different groups might avoid infringement.
- Alternative chemical frameworks outside the benzimidazole core could be explored.
6. Comparative Analysis with Similar Patents
| Patent/Compound |
Filing Year |
Key Features |
Potential Overlap |
Strategic Value |
| Glenmark 10,292,937 |
2017 |
Benzimidazoles with antiviral/antiparasitic activity |
Limited to specific substitutions |
High, given broad claims |
| Gilead's Remdesivir (US patent) |
2016 |
Nucleoside analogue antiviral |
Different structural class |
Complementary application areas |
| Bayer's Albendazole formulations |
2000s |
Benzimidazoles for antiparasitic use |
Similar core structure, different claims |
Competitive space |
7. Summary of Patent Strategy and Opportunities
- The patent's claims cover a broad chemical space within the benzimidazole class, particularly with substitutions aimed at antiviral/parasitic indications.
- The patent reinforces Glenmark's positioning in developing targeted therapies using this scaffold.
- Lifecycle management can include conducting further divisional or continuation applications to extend patent term.
- Licensing opportunities may exist through the compounds' promising activity profiles.
Key Takeaways
- U.S. Patent 10,292,937 secures rights over a broad yet specific class of benzimidazole compounds for therapeutic applications.
- The claims are sufficiently comprehensive to prevent straightforward design-arounds, but structural modifications outside claims can circumvent protections.
- The patent landscape indicates a competitive space with prior art, but Glenmark's specific substitutions and applications strengthen its patent position.
- Enforcement depends on the precise chemical structure and intended use; companies developing similar compounds must perform careful FTO analyses.
- Future patent filings can focus on compound optimization, formulations, or combination therapies to extend protection.
FAQs
Q1. What is the primary therapeutic focus of U.S. Patent 10,292,937?
The patent primarily covers benzimidazole derivatives intended for antiviral, antiparasitic, and possibly anticancer applications.
Q2. How broad are the chemical claims in the patent?
The claims encompass a wide class of benzimidazole compounds with various substitutions, covering both core structures and selected derivatives.
Q3. Can a competitor develop similar compounds outside these claims?
Yes, if the new compounds have sufficiently different structures or substitutions not covered by the claims, they may avoid infringement.
Q4. How does Glenmark defend against patent infringement?
By demonstrating that infringing compounds fall within the claims' scope, based on chemical structure and therapeutic use.
Q5. What is the patent landscape surrounding benzimidazole derivatives?
The landscape includes prior art with similar compounds but is distinguished by specific substitutions and therapeutic applications claimed by Glenmark.
References
[1] U.S. Patent 10,292,937. Benzimidazole derivatives for the treatment of diseases. May 14, 2019.
[2] WO 2015/174804. Benzimidazole derivatives with antiparasitic activity. 2014.
[3] EP 2659874. Benzimidazole-based antiviral agents. 2012.
[4] U.S. Patent 8,878,309. Benzimidazole compounds for cancer. 2014.
End of Document
